Equities Analysts Set Expectations for XOMA FY2025 Earnings

XOMA Co. (NASDAQ:XOMA) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of XOMA in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings of ($0.60) per share for the year, up from their previous forecast of ($0.97). The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s FY2026 earnings at $0.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $5.81 EPS.

Several other research analysts have also weighed in on XOMA. HC Wainwright reiterated a “buy” rating and issued a $104.00 price objective on shares of XOMA in a research report on Wednesday. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Stock Up 0.8 %

Shares of NASDAQ XOMA opened at $21.06 on Thursday. The company has a market capitalization of $248.15 million, a P/E ratio of -6.05 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a 50 day simple moving average of $24.45 and a 200-day simple moving average of $27.20. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.20% of the stock is currently owned by corporate insiders.

Institutional Trading of XOMA

A number of institutional investors and hedge funds have recently bought and sold shares of XOMA. BNP Paribas Financial Markets grew its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 1,183 shares during the period. Bank of America Corp DE raised its stake in shares of XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in XOMA during the 4th quarter worth $206,000. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.